A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors

• Sponsor: Qilu Pharmaceutical Co., Ltd. (Industry)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT05649761
• Collaborator: (none)
• Enrollment: 61
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 43.9
• Patients Per Site Per Month: 1.4

Study Details

Study Description

Brief Summary

This is a first-in-human (FIH), dose-escalation, PK expansion, monotherapy efficacy expansion, and open-label phase I clinical study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of QL1604 injection （a humanized anti-PD-1 monoclonal antibody）in patients with advanced solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Advanced Solid Tumors	Drug: QL1604 injection	Phase 1

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 61 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QL1604, a Humanized Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
• Actual Study Start Date: May 29, 2019
• Actual Primary Completion Date: Jul 10, 2020
• Anticipated Study Completion Date: Jan 23, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: QL1604 injection Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.	Drug: QL1604 injection; Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.

Outcome Measures

Primary Outcome Measures

1. Dose-limiting toxicity (DLT) [Up to 21 days after the first dose]

   Dose-limiting toxicity (DLT)

2. maximum tolerated dose(MTD) [Up to 21 days after the first dose]

   maximum tolerated dose(MTD)

3. recommended phase II dose (RP2D) [up to 2 years]

   recommended phase II dose (RP2D)

Secondary Outcome Measures

1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs [up to 2 years]

   according to NCI CTCAE V5.0

2. Maximum Concentration (Cmax) of QL1604 in Solid Tumor Participants [up to 2 years]

   Maximum Concentration (Cmax)

3. Time to Maximum Concentration (Tmax) of QL1604 in Solid Tumor Participants [up to 2 years]

   Time to Maximum Concentration (Tmax)

4. Terminal Half-Life (t ½) of QL1604 in Solid Tumor Participants [up to 2 years]

   Terminal Half-Life (t ½)

5. Area Under the Concentration-Time Curve of QL1604 From Time 0 to Day 28 (AUC 0-22) in Solid Tumor Participants [up to 22 days]

   Area Under the Concentration-Time Curve

6. Objective Response Rate (ORR) According to RECIST 1.1 [up to 2 years]

   Objective Response Rate (ORR) According to RECIST 1.1

7. Disease Control Rate (DCR) According to RECIST 1.1 [up to 2 years]

   Disease Control Rate (DCR) According to RECIST 1.1

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF);

2. Age ≥ 18 years and ≤ 70 years when ICF is signed;

3. Pts with histologically or cytologically confirmed advanced solid tumors;

4. At least one target lesion as defined per RECIST Version (v) 1.1;

5. Subjects who have disease progression or intolerable reactions after the currently available standard anti-cancer treatment previously received or refused prior cancer therapy regimen(s) ;

6. Eastern Cooperative Oncology Group performance status of 0 or 1;

7. Life expectancy of greater than 12 weeks;

8. Adequate hematologic and organ function;

9. Female subjects who are not pregnant or breastfeeding

10. Male and female subjects able to have children must agree to use highly effective method of contraception throughout the study and for at least 120 days after last dose;

Exclusion Criteria:

1. Known hypersensitivity to any monoclonal antibody, QL1604 and/or any of its excipients;

2. Active autoimmune disease that has required systemic treatment, replacement therapy is acceptable;

3. Subjects with major cardiovascular and cerebrovascular diseases;

4. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug;

5. Subjects who have received surgery, radiotherapy, chemotherapy, targeted therapy, other anti-tumor treatments, or participating in other clinical studies is less than 4 weeks before the first administration of investigational product;

6. Received a live vaccine;

7. Infection with human immunodeficiency virus (HIV);

8. Known psychiatric or substance abuse disorders that would interfere with the requirements of the study;

9. History or current evidence of any condition, therapy, or laboratory abnormality, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study, or investigators/sponsor consider the subjects are not suitable for this trial.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cancer Hospital of The University of Chinese Academy of Sciences	Hangzhou	Zhejiang	China	310022

Sponsors and Collaborators

• Qilu Pharmaceutical Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Qilu Pharmaceutical Co., Ltd.
• ClinicalTrials.gov Identifier: NCT05649761
• Other Study ID Numbers: QL1604-001
• First Posted: Dec 14, 2022
• Last Update Posted: Dec 14, 2022
• Last Verified: Nov 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Neoplasms

Study Results

No Results Posted as of Dec 14, 2022